Hot Features
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expres... Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.83 | -29.3286219081 | 2.83 | 2.91 | 1.66 | 647656 | 2.39315579 | CS |
| 4 | -0.33 | -14.1630901288 | 2.33 | 3.12 | 1.66 | 681427 | 2.47475502 | CS |
| 12 | -1.13 | -36.1022364217 | 3.13 | 3.62 | 1.66 | 811770 | 2.5521084 | CS |
| 26 | 0.96 | 92.3076923077 | 1.04 | 3.62 | 0.994949 | 1178217 | 2.16524012 | CS |
| 52 | 1.42 | 244.827586207 | 0.58 | 3.62 | 0.5439 | 731128 | 1.92857841 | CS |
| 156 | 0.77 | 62.6016260163 | 1.23 | 3.62 | 0.49 | 401147 | 1.76500531 | CS |
| 260 | -2.44 | -54.954954955 | 4.44 | 10.87 | 0.47 | 699671 | 3.1739881 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.